Key Takeaways AVNS beat Q4 EPS and revenue estimates, but shares fell nearly 10% yesterday.Avanos Medical's SNS sales rose 8.7%, led by enteral feeding and neonate solutions growth.AVNS guides 2026 sales of $700-$720M and EPS of 90 cents to $1.10 amid tariff headwinds.Avanos Medical, Inc. (AVNS) reported fourth-quarter 2025 adjusted earnings per share (EPS) from continuing operations of 29 cents, down 32.6% year over year. However, the bottom line beat the Zacks Consensus Estimate of 24 cents by 20.8%.GAAP ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 001-36440 Avanos Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (I.R.S. Employ ...

Pacitti said the SNS portfolio delivered “strong above market” performance in 2025, growing over 8% organically year over year. He cited strength across long-term, short-term, and neonatal enteral feeding, including support from Avanos’s “Go Direct” transition in the U.K. that was executed in the third quarter of 2025.In the quarter, Avanos reported $0.29 in adjusted diluted EPS and $28 million of adjusted EBITDA. Adjusted gross margin was 53.4% and adjusted SG&A was 39.1% of revenue. For the full year, adj ...

Avanos Medical (NYSE:AVNS) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsDave Pacitti - CEOJason Pickett - VP of Corporate Finance, Tax, and TreasurerScott Galovan - SVP and CFOConference Call ParticipantsDanny Stauder - Director and Equity Research AnalystOperatorNote that this call is being recorded on February 24th, 2026. I would now like to turn the conference over to Jason Pickett, Vice President, Corporate Finance and Treasurer. Please go ahead.Jason PickettGood morning, ever ...

Avanos Medical (NYSE:AVNS) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsDave Pacitti - CEOJason Pickett - VP of Corporate Finance, Tax , and TreasurerScott Galovan - SVP and CFOConference Call ParticipantsDanny Stauder - Director and Equity Research AnalystOperatorNote that this call is being recorded on February 24th, 2026. I would now like to turn the conference over to Jason Pickett, Vice President, Corporate Finance and Treasurer. Please go ahead.Jason PickettGood morning, eve ...

Financial Data and Key Metrics Changes - For the full year 2025, the company reported net sales of $701 million, exceeding the revised guidance range, and generated adjusted diluted earnings per share of $0.94 [4][11] - The adjusted EBITDA for the year was $87 million, with an adjusted gross margin of 54.6% and adjusted SG&A as a percentage of revenue of 42% [12][19] - For Q4 2025, net sales were approximately $181 million, with adjusted diluted earnings per share of $0.29 and adjusted EBITDA of $28 million [11][19] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems portfolio grew over 8% organically compared to the prior year, driven by strong demand in long-term and short-term enteral feeding products [6][15] - The Pain Management & Recovery portfolio saw normalized organic sales increase by 2.3%, with the radiofrequency ablation business posting double-digit organic growth [7][18] - The Game Ready portfolio experienced a slight decline year-over-year but maintained similar revenue levels throughout 2025 [9][18] Market Data and Key Metrics Changes - The Specialty Nutrition Systems segment's operating profit was 19%, down 100 basis points from the previous year due to unfavorable tariff impacts [17] - The Pain Management & Recovery segment's operating profit improved by 270 basis points to 4%, reflecting effective cost management despite tariff costs [18] - The hyaluronic acid injections and IV therapy product lines reported a decline of over 35% compared to the prior year due to the divestiture of the HA business [19] Company Strategy and Development Direction - The company is focused on five strategic imperatives: accelerating organic growth, managing tariff impacts, realizing operating efficiencies, improving or divesting underperforming assets, and acquiring synergistic businesses [10][23] - The company is executing a China exit strategy, aiming to have all syringe manufacturing operations out of China by June 2026 [12][21] - The integration of Nexus Medical into the neonatal portfolio is progressing well, with expectations for double-digit growth in 2026 [13][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for continued growth in 2026, despite anticipated tariff impacts [20][23] - The company expects net sales in the range of $700 million to $720 million for 2026, with mid to high single-digit growth in the Specialty Nutrition Systems segment [21] - Management highlighted the importance of ongoing tariff mitigation strategies and the expected improvement in gross margins in the second half of 2026 [20][34] Other Important Information - The company generated $43 million of free cash flow for the full year, higher than anticipated due to timing of one-time cash charges [19][20] - Capital expenditures for 2026 are expected to be around $25 million, slightly lower than 2025, to support the accelerated China exit plan [22] Q&A Session Summary Question: Insights on tariffs and 2026 outlook - Management estimated a $30 million impact from tariffs in 2026, with a significant portion related to China [27][29] - The company is confident in exiting China by June and delivering products from Mexico and Cambodia [28][30] Question: Revenue guidance and organic growth rates - The consolidated organic growth rate is expected to be around 5%, with mid to high single digits for Specialty Nutrition Systems and low to mid single digits for Pain Management & Recovery [36][37] Question: Operating leverage and cost-saving initiatives - Management expressed high confidence in continuing to drive efficiency in 2026, with a focus on both R&D and SG&A [38][39] - Cost containment measures are expected to offset additional tariff expenses and support earnings expansion [41] Question: Specialty Nutrition performance and Nexus acquisition - Demand for the Specialty Nutrition Systems portfolio remains high, with Nexus performing better than expected and contributing to growth [42][44]

Getting patients back to what matters. Dave Pacitti Chief Executive Officer Q4/FY Overview & Business Update Q4 & Full Year 2025 Earnings Presentation February 24, 2026 Scott Galovan SVP, Chief Financial Officer Q4/FY Results & 2026 Planning Assumptions DISCLAIMER REGARDING FORWARD-LOOKING STATEMENTS Certain matters in this presentation, including expectations and planning assumptions, any comments about our expected performance, and any estimates, projections, or statements relating to our business plans, ...

Investor Contact: Scott Galovan Avanos Medical, Inc. 470-562-2692 Investor.Relations@Avanos.com Media Contact: Katrine Kubis Avanos Medical, Inc. CorporateCommunications@Avanos.com Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results ALPHARETTA, Ga., February 24, 2026/PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2025 results. "I'm very pleased with our fourth quarter and full-year results, which demonstrate meaningful progress on our strate ...

Core Viewpoint - Avanos Medical, Inc. will host a conference call on February 24, 2026, to discuss its financial results for the fourth quarter and full year 2025, with a news release to be issued prior to market opening on the same day [1] Company Overview - Avanos Medical, Inc. is a medical technology company headquartered in Alpharetta, Georgia, focused on delivering clinically superior medical device solutions to address significant healthcare needs [1] - The company aims to provide essential nutrition to patients transitioning from hospital to home and to reduce opioid use while facilitating recovery from surgery [1] - Avanos develops, manufactures, and markets recognized brands globally, holding leading market positions in multiple product categories [1]

Core Insights - Avanos Medical (AVNS) and Siemens Healthineers have entered a strategic co-marketing agreement to enhance outpatient and interventional pain management by integrating advanced imaging with radiofrequency ablation (RFA) technologies [2][10] - The partnership reflects a trend of shifting complex pain procedures from hospitals to outpatient settings, focusing on flexible and cost-efficient solutions that improve clinical outcomes [3][8] Company Collaboration - The collaboration combines AVNS' RFA expertise with Siemens Healthineers' imaging technologies, aiming to improve procedural precision and broaden access to outpatient pain management solutions [4][5] - Siemens Healthineers' mobile C-arm systems, such as Cios Select and Cios Flow, will enhance imaging performance and support operational efficiency in pain management procedures [5][6] Strategic Implications - The agreement allows both companies to leverage existing strengths, enhancing AVNS' RFA portfolio and extending Siemens Healthineers' mobile C-arm systems into outpatient specialties [7] - The initial focus on the U.S. market, along with joint education and marketing initiatives, suggests a strategy aimed at accelerating adoption of these technologies [8] Industry Context - The pain management sector is witnessing strategic innovations from major MedTech players like Teleflex, Stryker, and Baxter, each pursuing unique approaches to meet evolving clinical needs [9] - Teleflex focuses on regional anesthesia solutions to enhance procedural safety and efficiency, while Stryker emphasizes minimally invasive outpatient solutions for spinal conditions [11][12] - Baxter offers ready-to-use formulations for local or regional anesthesia, streamlining administration and enhancing procedural efficiency [13]